Neon Therapeutics
Focused on unlocking the full potential of the immune system to recognize and attack cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD104m (Public information from Jan 2020)
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenues | - | - | 10.0m |
| EBITDA | (77.0m) | (78.0m) | (60.0m) |
| % EBITDA margin | - | - | (600 %) |
| Profit | (76.0m) | (79.0m) | (67.0m) |
| % profit margin | - | - | (670 %) |
| R&D budget | 58.3m | 58.3m | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$55.0m | Series A | ||
$70.0m | Series B | ||
* | $106m Valuation: $125m | Series B | |
| N/A | $100m Valuation: $451m | IPO | |
$67.0m Valuation: $67.0m -0.8x EV/LTM EBITDA | Acquisition | ||
| Total Funding | AUD357m | ||
Related Content
Recent News about Neon Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.